Formoterol fumarate inhalation solution (Perforomist™) for COPD

References

• Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med.176(6), 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson GP, Linden A, Rabe KF. Why are long-acting β-adrenoceptor agonists long-acting? Eur. Respir. J.7(3), 569–578 (1994).
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Mak JC, Barnes PJ. Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lung. Eur. J. Pharmacol.318(1), 123–129 (1996).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Airway subsensitivity with long-acting β2-agonists. Is there cause for concern? Drug Safety16(5), 295–308 (1997).
   PubMed Web of Science ®Google Scholar
• Lee DK, Currie GP, Hall IP et al. The arginine-16 β2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol.57(1), 68–75 (2004).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Centanni S, Regorda C et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm. Pharmacol. Ther.14(1), 41–45 (2001).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, D’Amato M et al. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulm. Pharmacol. Ther.16(2), 105–109 (2003).
   Google Scholar
• Cazzola M, Santangelo G, Piccolo A et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol.7(2), 103–107 (1994).
   PubMedGoogle Scholar
• Maesen BL, Westermann CJ, Duurkens VA et al. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur. Respir. J.13(5), 1103–1108 (1999).
   PubMedGoogle Scholar
• Benhamou D, Cuvelier A, Muir JF et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir. Med.95(10), 817–821 (2001).
   PubMed Web of Science ®Google Scholar
• Di Marco F, Milic-Emili J, Boveri B et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur. Respir. J.21(1), 86–94 (2003).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D’Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose–response study. Respir. Med.89(5), 357–362 (1995).
   PubMed Web of Science ®Google Scholar
• Celik G, Kayacan O, Beder S et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration66(5), 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Kottakis J, Cioppa GD, Creemers J et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J.9(2), 107–115 (2002).
   PubMedGoogle Scholar
• Molimard M, Bourcereau J, Le Gros V, Bourdeix I. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Respir. Med.99(6), 695–702 (2005).
   Google Scholar
• Aalbers R, Ayres J, Backer V et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur. Respir. J.19(5), 936–943 (2002).
   PubMed Web of Science ®Google Scholar
• Campbell M, Eliraz A, Johansson G et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir. Med.99(12), 1511–1520 (2005).
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.164(5), 778–784 (2001).
   PubMed Web of Science ®Google Scholar
• Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin. Ther.25(1), 285–297 (2003).
   PubMed Web of Science ®Google Scholar
• O’Donnell TDE. Is sustained pharmacologic lung volume reduction now possible in COPD? Chest129(3), 501–503 (2006).
   PubMed Web of Science ®Google Scholar
• Dougherty JA, Didur BL, Aboussouan LS. Long-acting inhaled β2-agonists for stable COPD. Ann. Pharmacother.37(9), 1247–1255 (2003).
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD4(3), 225–236 (2007).
   PubMedGoogle Scholar
• Chhabra SK, Vijayan VK, Vasu T. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J. Chest Dis. Allied Sci.48(2), 97–102 (2006).
   Google Scholar
• Liesker JJ, Van DV, V, Meysman M et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med.96(8), 559–566 (2002).
   PubMed Web of Science ®Google Scholar
• Neder JA, Fuld JP, Overend T et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir. Med.101(10), 2056–2064 (2007).
   PubMed Web of Science ®Google Scholar
• Mahler DA. The effect of inhaled β2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol.110(6 Suppl.), S298–S303 (2002).
   Google Scholar
• Brown CD, Wise RA. Field tests of exercise in COPD: the six-minute walk test and the shuttle walk test. COPD4(3), 217–223 (2007).
   PubMedGoogle Scholar
• Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest121(4), 1058–1069 (2002).
   PubMed Web of Science ®Google Scholar
• Wadbo M, Lofdahl CG, Larsson K et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur. Respir. J.20(5), 1138–1146 (2002).
   PubMed Web of Science ®Google Scholar
• Berry MJ. The relationship between exercise tolerance and other outcomes in COPD. COPD4(3), 205–216 (2007).
   PubMedGoogle Scholar
• D’Urzo AD, De Salvo MC, Ramirez-Rivera A et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest119(5), 1347–1356 (2001).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Di Marco F, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther.17(1), 35–39 (2004).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Noschese P, Salzillo A, De Giglio C, D’Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir. Med.99(5), 524–528 (2005).
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J.26(2), 214–222 (2005).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD. Pulm. Pharmacol. Ther.16(4), 197–201 (2003).
   Google Scholar
• Cazzola M, Di Perna F, D’Amato M, Califano C, Matera MG, D’Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir. Med.95(11), 917–921 (2001).
   PubMed Web of Science ®Google Scholar
• Cazzola M, D’Amato M, Califano C et al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther.24(4), 595–604 (2002).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Santus P, Matera MG et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir. Med.97(5), 458–462 (2003).
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir. Med.100(11), 1925–1932 (2006).
   PubMed Web of Science ®Google Scholar
• Colice GL, Carnathan B, Sung J et al. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J. Asthma42(1), 29–34 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir. Med.89(2), 79–84 (1995).
   PubMed Web of Science ®Google Scholar
• Goldkorn A, Diotto P, Burgess C et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology9(1), 102–108 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell SC, Criner GJ, Levine BE et al. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther.20(5), 571–579 (2007).
   PubMed Web of Science ®Google Scholar
• Formoterol (Perforomist) for COPD. Med. Lett. Drugs Ther.49(1274), 94–95 (2007).
   Google Scholar
• van der Woude HJ, Zaagsma J, Postma DS et al. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest127(3), 818–824 (2005).
   PubMed Web of Science ®Google Scholar
• Gross NJ, Nelson HS, Lapidus RJ et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir. Med.102(2), 189–197 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson HS, ZuWallack R, Levine B et al. Safety profile of formoterol fumarate delivered by nebulization to COPD patients. Am. J. Respir. Crit. Care Med.175, A128 (2007).
   Google Scholar
• Nelson HS, Gross NJ, Levine B et al. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin. Ther.29(10), 2167–2178 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest120(1), 258–270 (2001).
   PubMed Web of Science ®Google Scholar
• Busquets S, Figueras MT, Fuster G et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res.64(18), 6725–6731 (2004).
   PubMed Web of Science ®Google Scholar